{
"id":"mk19_a_on_t04",
"number":4,
"bookId":"on",
"title":{
"__html":"American Cancer Society Recommendations for MRI Breast Cancer Screening"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"7dbbc0",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 4. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_on_t04"
}
]
},
"American Cancer Society Recommendations for MRI Breast Cancer Screening"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0e9fd",
"class":"cell txt l",
"children":[
"Women with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1/2"
]
},
" mutations"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea326c",
"class":"cell txt l",
"children":[
"Women who are a first-degree relative of a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1/2"
]
},
" carrier but are untested",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"18f0d8",
"class":"cell txt l",
"children":[
"Women with a strong family history of breast cancer with a lifetime breast cancer risk of ≥20% to 25% as calculated by models",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
" largely dependent on family history"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"775284",
"class":"cell txt l",
"children":[
"Women who had radiation to the chest wall between ages 10 and 30 years (e.g., mantle radiation therapy for Hodgkin lymphoma)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff6570",
"class":"cell txt l",
"children":[
"Women with a history of other rare familial breast cancer syndromes"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1/2"
]
},
" = breast cancer susceptibility 1 or breast cancer susceptibility 2 genes."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Testing for the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
" or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA2"
]
},
" mutation that is present in the family is strongly recommended, but some patients decide to defer testing. In this situation when their carrier status is unknown, breast MRI screening is recommended. If they are later tested and do not carry the mutation, MRI screening should be stopped."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Models that can be used to estimate lifetime risk of breast cancer to determine if MRI screening is appropriate (please note that the Gail Model is not recommended for this use):"
],
[
"BRCAPRO: ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www4.utsouthwestern.edu/breasthealth/cagene/default.asp",
"target":"_blank"
},
"children":[
"www4.utsouthwestern.edu/breasthealth/cagene/default.asp"
]
}
],
[
"Claus model: Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first-degree family history of ovarian cancer. Breast Cancer Res Treat. 1993 Nov;28(2):115–20. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/8173064",
"target":"_blank"
},
"children":[
"PMID: 8173064"
]
}
],
[
"Tyrer-Cuzik (also called IBIS Breast Cancer Risk Evaluation Tool): ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ems-trials.org/riskevaluator/",
"target":"_blank"
},
"children":[
"www.ems-trials.org/riskevaluator/"
]
}
]
]
}